Evidence map›Paper›PMID 31576146›Full record

ArticleOncoTargets and therapy2019

Enumeration And Characterization Of Circulating Tumor Cells And Its Application In Advanced Gastric Cancer.

Boran Cheng, Gangling Tong, Xuan Wu, Wenwu Cai, Zhu Li, Zhongyi Tong, Lirui He, Shaokang Yu, Shubin Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Circulating tumor cells in colorectal cancer in the era of precision medicine.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Boran Cheng *Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China.
Gangling Tong *Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China.
Xuan Wu *Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China.ORCID 0000-0002-5622-1908
Wenwu Cai *Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province 410011, People's Republic of China.
Zhu Li *Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China.
Zhongyi TongDepartment of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province 410011, People's Republic of China.
Lirui HeDepartment of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China.
Shaokang YuDepartment of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China.
Shubin WangDepartment of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province 518036, People's Republic of China.
Peking University Shenzhen Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced gastric cancer (aGC) has a high global incidence and a high mortality rate and because of its high malignancy and heterogeneity, the existing methods for prognosis are limited, and a new treatment model is necessary. Circulating tumor cells (CTCs) could be considered as a "liquid biopsy" for tumor diagnosis and for monitoring treatment responses and predicting clinical outcome. Clinical studies support the efficacy of programmed cell death 1 (PD-1) immunotherapy in a subset of aGC.

methodsCell capture efficiency, as described by the CanPatrol CTC enrichment technique, was validated using artificial blood samples as well as blood samples from 32 aGC patients. Clinicopathologic data of patients were collected from the hospital information system. We used CanPatrol for CTC isolation, classification, and clinical analysis.

resultsA cell capture efficiency of >80% was achieved. Significant correlation was observed between CTC enumeration and clinicopathology parameters, including the Lauren classification (r=0.470, P=0.008), perineural invasion (r=0.393, P=0.029), TNM stage (r=0.740, P<0.001), and Ki-67 level (r=0.510, P=0.005). When compared to the traditional methods, monitoring CTC subtypes exhibits higher sensitivity of evaluating the disease status. Enumeration of epithelial CTC subset and its relative abundance in the total CTC pool are highly correlated with clinical efficacy. CTC programmed cell death ligand-1 (PD-L1) could be successfully detected for immunotherapy in addition to PD-L1 immunohistochemistry and microsatellite instability.

conclusionWe provide a new method that allows for the simple and effective detection of CTCs in aGC. It has potential clinical applications in monitoring prognosis and guiding future individualized immunotherapy.

Indexed as

clinical response predictionCTC enumerationimmune checkpoint therapysubgroup analysis

Identifiers

PMID31576146
PMCPMC6768312
OpenAlexW2975227583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.